Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.


There is an increasing trend among physicians to use 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in combination with other antilipidemic agents. The complementary lipid-altering effects of statins and fibric acid derivatives (fibrates) have led to an increasing use of statin/fibrate

PMID: 15619408

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.